Opinion|Videos|November 27, 2024

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

Key Takeaways

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME